Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer
Executive Summary
The French biotech's shares have sunk 30% but Erytech's decision to withdraw its European marketing authorization application for Graspa in the crowded acute lymphoblastic leukemia market, and focus solely on solid tumors, has gone down well with analysts.
You may also be interested in...
Erytech’s Solid Tumor Hopes Falter As Eryaspase Fails In Phase III Pancreatic Cancer Trial
Erytech’s eryaspase has failed in its Phase III TRYbeCA-1 trial for second-line pancreatic cancer despite analyst excitement for the solid tumor indication. Its attentions now turn, once again, to its acute lymphoblastic leukemia indication.
Eight Oncology Drug Launches Expected In 2022 – Solid Tumors
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.